Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Colorectal cancer
Immunotherapy
MMR
MMR deficiency
MSI
PD-1/PD-L1
Solid tumors
Tumor-agnostic therapy
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
03
11
2021
revised:
11
01
2022
accepted:
11
01
2022
pubmed:
17
1
2022
medline:
9
2
2022
entrez:
16
1
2022
Statut:
ppublish
Résumé
Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to immune-checkpoint inhibitors (ICIs) in patients with solid tumors. In October 2016, the FDA granted pembrolizumab as breakthrough therapy for the treatment of non-CRC, MSI-H/dMMR tumors, providing, for the first time, a tumor-agnostic indication. In the next future, the tissue-agnostic evaluation of MSI-H/dMMR could become the common denominator for the immunotherapy treatment of patients with different advanced solid tumors, in order to select patient subgroups which may benefit from this therapy. In this Review we provided an overview of the main clinical studies describing the association between MSI-H/dMMR tumors and immunotherapy response.
Identifiants
pubmed: 35033663
pii: S1040-8428(22)00021-X
doi: 10.1016/j.critrevonc.2022.103597
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103597Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.